诺诚健华:子公司与Zenas签署授权许可协议,本次潜在交易总价值超过20亿美元

华尔街见闻
Oct 08

诺诚健华公告称,公司全资子公司InnoCarePharmaInc.与ZenasBioPharma,Inc.签署授权许可协议,将具有自主知识产权的产品奥布替尼及2项临床前资产有偿许可给Zenas,使其可以开发、生产、商业化或以其他方式利用该等产品。交易金额包括1亿美元首付款和700万普通股股票,以及潜在的研发及注册里程碑付款,总额超过20亿美元。协议自双方签订之日起生效,持续到所许可产品的销售特许权...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10